PMID- 29438368
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 118
IP  - 6
DP  - 2018 Mar 20
TI  - Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during
      radiotherapy in melanoma patients.
PG  - 785-792
LID - 10.1038/bjc.2017.489 [doi]
AB  - This corrects the article DOI: 10.1038/bjc.2017.85.
FAU - Hecht, Markus
AU  - Hecht M
AD  - Department of Radiation Oncology, University Hospital Erlangen, Erlangen,
      Germany.
FAU - Meier, Friedegund
AU  - Meier F
AD  - Department of Dermatology, University Hospital Dresden, Dresden, Germany.
FAU - Zimmer, Lisa
AU  - Zimmer L
AD  - Department of Dermatology, University Hospital Essen, Essen, Germany.
FAU - Polat, Bulent
AU  - Polat B
AD  - Department of Radiation Oncology, University Hospital Wurzburg, Wurzburg,
      Germany.
FAU - Loquai, Carmen
AU  - Loquai C
AD  - Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
FAU - Weishaupt, Carsten
AU  - Weishaupt C
AD  - Department of Dermatology, University Hospital Munster, Munster, Germany.
FAU - Forschner, Andrea
AU  - Forschner A
AD  - Department of Dermatology, University Hospital Tubingen, Tubingen, Germany.
FAU - Gutzmer, Ralf
AU  - Gutzmer R
AD  - Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover
      Medical School, Hannover, Germany.
FAU - Utikal, Jochen S
AU  - Utikal JS
AD  - Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Dermatology, Venereology and Allergology, University Medical Center
      Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
FAU - Goldinger, Simone M
AU  - Goldinger SM
AD  - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
FAU - Geier, Michael
AU  - Geier M
AD  - Department of Radiation Oncology, Ordensklinikum Linz, Linz, Austria.
FAU - Hassel, Jessica C
AU  - Hassel JC
AD  - Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
FAU - Balermpas, Panagiotis
AU  - Balermpas P
AD  - Department of Radiation Oncology, University Hospital Frankfurt, Frankfurt,
      Germany.
FAU - Kiecker, Felix
AU  - Kiecker F
AD  - Department of Dermatology, University Hospital Berlin, Berlin, Germany.
FAU - Rauschenberg, Ricarda
AU  - Rauschenberg R
AD  - Department of Dermatology, University Hospital Dresden, Dresden, Germany.
FAU - Dietrich, Ursula
AU  - Dietrich U
AD  - Department of Dermatology, University Hospital Dresden, Dresden, Germany.
FAU - Clemens, Patrick
AU  - Clemens P
AD  - Department of Radiation Oncology, Hospital Feldkirch, Feldkirch, Austria.
FAU - Berking, Carola
AU  - Berking C
AD  - Department of Dermatology, University Hospital LMU Munich, Munchen, Germany.
FAU - Grabenbauer, Gerhard
AU  - Grabenbauer G
AD  - Department of Radiation Oncology, Hospital Coburg, Coburg, Germany.
FAU - Schadendorf, Dirk
AU  - Schadendorf D
AD  - Department of Dermatology, University Hospital Essen, Essen, Germany.
FAU - Grabbe, Stephan
AU  - Grabbe S
AD  - Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
FAU - Schuler, Gerold
AU  - Schuler G
AD  - Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
FAU - Fietkau, Rainer
AU  - Fietkau R
AD  - Department of Radiation Oncology, University Hospital Erlangen, Erlangen,
      Germany.
FAU - Distel, Luitpold V
AU  - Distel LV
AD  - Department of Radiation Oncology, University Hospital Erlangen, Erlangen,
      Germany.
FAU - Heinzerling, Lucie
AU  - Heinzerling L
AD  - Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180213
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Imidazoles)
RN  - 0 (Oximes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 207SMY3FQT (Vemurafenib)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Imidazoles/administration & dosage
MH  - Male
MH  - Melanoma/*drug therapy/enzymology/*radiotherapy
MH  - Middle Aged
MH  - Oximes/administration & dosage
MH  - Protein Kinase Inhibitors/administration & dosage
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
MH  - Radiation-Sensitizing Agents/administration & dosage
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy/enzymology/*radiotherapy
MH  - Treatment Outcome
MH  - Vemurafenib/administration & dosage
MH  - Young Adult
PMC - PMC5886123
EDAT- 2018/02/14 06:00
MHDA- 2019/04/16 06:00
CRDT- 2018/02/14 06:00
PHST- 2017/07/27 00:00 [received]
PHST- 2017/12/11 00:00 [revised]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2018/02/14 06:00 [entrez]
AID - bjc2017489 [pii]
AID - 10.1038/bjc.2017.489 [doi]
PST - ppublish
SO  - Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb
      13.